{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T04:25:56Z","timestamp":1768883156289,"version":"3.49.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>To review the updated 2023 Allergy Immunology Joint Task Force on Practice Parameters (JTFPP) GRADE and Institute of Medicine (IOM) Based Guidelines for the management of atopic dermatitis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Topical corticosteroids and\/or calcineurin inhibitors are recommended in individuals with atopic dermatitis refractory to moisturizer alone and may be used to maintain remission after acute flare control is achieved. Calcineurin inhibitors are a class of immunosuppressants used to effectively manage different autoimmune disorders. Bleach baths and allergen immunotherapy may be beneficial for individuals with moderate-to-severe disease, while elimination diets, azathioprine, methotrexate, mycophenolate, and systemic corticosteroids are not recommended. Dupilumab is strongly recommended for refractory atopic dermatitis. Oral Janus kinase (JAK) inhibitors carry significant risks; however, this class of medicines may be considered in cases of severe or refractory atopic dermatitis with intolerance to dupilumab. Patient preferences regarding cost, availability, feasibility, and tolerability should be integrated into all treatment plans using a shared decision-making approach.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The 2023 JTFPP Atopic Dermatitis Guidelines offer up-to-date guidance for the management of atopic dermatitis of varying severity in infants, children, and adults.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000001381","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T04:06:13Z","timestamp":1719979573000},"page":"570-580","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Pearls for practice from the 2023 allergy immunology joint task force on practice parameters GRADE and institute of medicine based atopic dermatitis guidelines"],"prefix":"10.1097","volume":"36","author":[{"given":"Alexandra E.","family":"Conway","sequence":"first","affiliation":[{"name":"Geisel School of Medicine at Dartmouth, Hanover, New Hampshire"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navya","family":"Kartha","sequence":"additional","affiliation":[{"name":"Akron Children's Hospital, Department of Pediatrics, Akron"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaitanya","family":"Maddukuri","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Southpointe, Department of Medicine, Cleveland, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus S.","family":"Shaker","sequence":"additional","affiliation":[{"name":"Geisel School of Medicine at Dartmouth, Departments of Medicine and Pediatrics, Hanover"},{"name":"Dartmouth-Hitchcock Medical Center, Section of Allergy and Immunology, Lebanon, New Hampshire, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"key":"R1-20250730","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","article-title":"Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R2-20250730","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jaci.2013.08.031","article-title":"Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study","volume":"132","author":"Silverberg","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"R3-20250730","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","article-title":"Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations","volume":"132","author":"Panel AAJADG","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R5-20250730","article-title":"Patient-centered practice guidelines: GRADEing Evidence to Incorporate Certainty, Balance Between Benefits and Harms, Equity, Feasibility, and Cost-Effectiveness","volume":"S2213-2198","author":"Stephen","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R6-20250730","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.anai.2020.03.009","article-title":"Making the GRADE in anaphylaxis management: toward recommendations integrating values, preferences, context, and shared decision making","volume":"124","author":"Shaker","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R7-20250730","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1398-9995.2010.02530.x","article-title":"Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations","volume":"66","author":"Brozek","year":"2011","journal-title":"Allergy"},{"key":"R8-20250730","first-page":"CD012119","article-title":"Emollients and moisturisers for eczema","volume":"2","author":"van Zuuren","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R9-20250730","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2352-4642(22)00146-8","article-title":"Effectiveness and safety of lotion, cream, gel, and ointment emollients for childhood eczema: a pragmatic, randomised, phase 4, superiority trial","volume":"6","author":"Ridd","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"R10-20250730","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jaci.2023.08.030","article-title":"Topical treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials","volume":"152","author":"Chu","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"R11-20250730","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamadermatol.2022.6045","article-title":"Values and preferences of patients and caregivers regarding treatment of atopic dermatitis (Eczema): a systematic review","volume":"159","author":"Maleki-Yazdi","year":"2023","journal-title":"JAMA Dermatol"},{"key":"R12-20250730","first-page":"CD013356","article-title":"Strategies for using topical corticosteroids in children and adults with eczema","volume":"3","author":"Lax","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"R13-20250730","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaip.2014.02.015","article-title":"Clinical management of atopic dermatitis: practical highlights and updates from the atopic dermatitis practice parameter 2012","volume":"2","author":"Lio","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R14-20250730","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S2352-4642(22)00283-8","article-title":"Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis","volume":"7","author":"Devasenapathy","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"R15-20250730","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.iac.2016.08.003","article-title":"Wet wrap therapy in moderate to severe atopic dermatitis","volume":"37","author":"Nicol","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"key":"R16-20250730","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaip.2014.04.009","article-title":"Wet wrap therapy in children with moderate to severe atopic dermatitis in a multidisciplinary treatment program","volume":"2","author":"Nicol","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R17-20250730","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.jaad.2020.03.074","article-title":"Framing atopic dermatitis topical medication application site discomfort as a signal of efficacy improves willingness to continue use","volume":"83","author":"Bashyam","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R18-20250730","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jaci.2023.08.029","article-title":"Systemic treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials","volume":"152","author":"Chu","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"R19-20250730","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40257-022-00690-3","article-title":"A maximum-use trial of ruxolitinib cream in adolescents and adults with atopic dermatitis","volume":"23","author":"Bissonnette","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"R20-20250730","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"R21-20250730","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.anai.2022.03.024","article-title":"Bleach baths for atopic dermatitis: a systematic review and meta-analysis including unpublished data, Bayesian interpretation, and GRADE","volume":"128","author":"Bakaa","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R22-20250730","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jpeds.2021.10.011","article-title":"Separating fact from fiction in the diagnosis and management of food allergy","volume":"241","author":"Abrams","year":"2022","journal-title":"J Pediatr"},{"key":"R23-20250730","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.anai.2024.01.018","article-title":"Serologic measurements for peanut allergy: predicting clinical severity is complex","volume":"132","author":"Conway","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R24-20250730","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jaci.2021.03.014","article-title":"Leveraging shared decision making to discuss nonessential medical testing and prevent peanut allergy overdiagnosis during infancy","volume":"148","author":"Greenhawt","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"R25-20250730","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jaci.2020.07.031","article-title":"Peanut allergy diagnosis: a 2020 practice parameter update, systematic review, and GRADE analysis","volume":"146","author":"Greenhawt","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"R26-20250730","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1414850","article-title":"Randomized trial of peanut consumption in infants at risk for peanut allergy","volume":"372","author":"Du Toit","year":"2015","journal-title":"N Engl J Med"},{"key":"R27-20250730","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1016\/j.jaip.2022.06.044","article-title":"Dietary elimination for the treatment of atopic dermatitis: a systematic review and meta-analysis","volume":"10","author":"Oykhman","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R28-20250730","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.immuni.2020.12.013","article-title":"Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response","volume":"54","author":"Golebski","year":"2021","journal-title":"Immunity"},{"key":"R29-20250730","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.jaci.2017.10.010","article-title":"Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers","volume":"140","author":"Shamji","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"R30-20250730","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00105-021-04909-y","article-title":"[Allergen immunotherapy for atopic dermatitis]","volume":"72","author":"Traidl","year":"2021","journal-title":"Hautarzt"},{"key":"R31-20250730","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jaci.2022.09.020","article-title":"Allergen immunotherapy for atopic dermatitis: systematic review and meta-analysis of benefits and harms","volume":"151","author":"Yepes-Nunez","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"R32-20250730","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1056\/NEJMc2300703","article-title":"Dupilumab in patients with eosinophilic esophagitis","volume":"388","author":"Greuter","year":"2023","journal-title":"N Engl J Med"},{"key":"R33-20250730","doi-asserted-by":"crossref","first-page":"97","DOI":"10.18176\/jiaci.0682","article-title":"Dupilumab: a review of present indications and off-label uses","volume":"32","author":"Munoz-Bellido","year":"2022","journal-title":"J Investig Allergol Clin Immunol"},{"key":"R34-20250730","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jaci.2022.10.026","article-title":"The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis","volume":"151","author":"Rank","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"R35-20250730","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s40257-023-00809-0","article-title":"Assessment of efficacy and safety outcomes beyond week 16 in clinical trials of systemic agents used for the treatment of moderate to severe atopic dermatitis in combination with topical corticosteroids","volume":"24","author":"Silverberg","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"R36-20250730","doi-asserted-by":"crossref","first-page":"e002735","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"R37-20250730","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamadermatol.2020.0218","article-title":"Evaluation for skin cancer and precancer in patients with vitiligo treated with long-term narrowband UV-B phototherapy","volume":"156","author":"Bae","year":"2020","journal-title":"JAMA Dermatol"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T18:01:14Z","timestamp":1753898474000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001381","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,18]]}}}